- Dec 01, 2023 Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
- Nov 02, 2023 Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
- Oct 24, 2023 Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
- Oct 13, 2023 Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
- Oct 04, 2023 Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
- Sep 05, 2023 Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
- Aug 31, 2023 Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
- Aug 08, 2023 Foghorn Therapeutics Announces Chief Medical Officer Succession
- Aug 04, 2023 Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
- Jun 28, 2023 Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
Displaying 1 - 10 of 20